Phaim Pharma Ltd
Our vision is to create a world where no one has to live with an autoimmune disease.
Our vision is to create a world where no one has to live with an autoimmune disease.
We are a London-based biotechnology company developing a novel therapeutic platform, known as Antigenic Immune Modulation (AIM), designed to cure, improve, halt or prevent autoimmune disease. Our lead drug candidate targets Type 1 Diabetes (T1D), with a pipeline that includes psoriasis, rheumatoid arthritis, and multiple sclerosis. We are committed to transforming the lives of those affected by autoimmune disease and delivering life-changing therapies.
There is no investment information
No recent news or press coverage available for Phaim Pharma Ltd.
We care about your data, and we'd love to use cookies make your experience better.
